Sandoz Group AG ADR D8Y0
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €80.00
- Day Range
- €80.50–80.50
- 52-Week Range
- —–80.50
- Bid/Ask
- €81.50 / €83.00
- Shares Outstanding
- 432.69M
- Market Cap
- €34.83B
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 41.38
- Price/Sales
- 3.33
- Dividend Yield (Trailing)
- 1.10%
- Dividend Yield (Forward)
- 1.10%
- Dividend Payment Schedule
- May
- Total Yield
- 1.10%
Company Profile
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz’s total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe’s first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 30 assets in its pipeline.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Growth
- Total Number of Employees
- 23,000
- Website
- https://www.sandoz.com
Competitors
Valuation
|
Metric
|
D8Y0
|
TEVA
|
RDY
|
|---|---|---|---|
Price/Earnings (Normalized) | 41.38 | 17.24 | 30.85 |
Price/Book Value | 4.17 | 6.20 | 2.64 |
Price/Sales | 3.33 | 2.77 | 2.91 |
Price/Cash Flow | 34.22 | 15.95 | 18.62 |
Price/Earnings
D8Y0
TEVA
RDY
Financial Strength
|
Metric
|
D8Y0
|
TEVA
|
RDY
|
|---|---|---|---|
Quick Ratio | 0.50 | 0.46 | 1.31 |
Current Ratio | 1.05 | 0.88 | 1.90 |
Interest Coverage | 4.66 | 1.79 | 10.27 |
Quick Ratio
D8Y0
TEVA
RDY
Profitability
|
Metric
|
D8Y0
|
TEVA
|
RDY
|
|---|---|---|---|
Return on Assets (Normalized) | 7.69% | 6.68% | 7.17% |
Return on Equity (Normalized) | 18.79% | 35.32% | 10.86% |
Return on Invested Capital (Normalized) | 12.29% | 14.43% | 9.39% |
Return on Assets
D8Y0
TEVA
RDY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|M&gR%@Wg | LOCK|^@JS# | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|##$DndDv | LOCK|lfbz | $49B | |||
| Haleon PLC ADR
HLN
| LOCK|vrT#f^j | LOCK|$^ | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|>%>H?>fW | LOCK|%#! | $32B | |||
| Viatris Inc
VTRS
| LOCK|q%<rlH | LOCK|hD@ | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|q$ | LOCK|C#> | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|&pB%@! | LOCK|>F | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|Sxh!k&^ | LOCK|@h | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|<YmXx!M | LOCK|?W$?z | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|$hPxdG | LOCK|??W | $2B |
United States